08:36 EST Theravance Biopharma (TBPH) says Phase 3 CYPRESS Study did not meet primary endpoint
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma trading halted, news pending
- Largest borrow rate increases among liquid names
- Theravance Biopharma price target raised to $27 from $20 at H.C. Wainwright
- TBPH Earnings this Week: How Will it Perform?
- Theravance Biopharma: Asymmetric Upside from Ampreloxetine on Top of a Cash-Flow-Positive Base Business Supports Buy Rating